Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name Durvalumab
Synonyms
Therapy Description

Imfinzi (durvalumab) is a monoclonal antibody that binds to and inhibits PD-L1 (CD274), potentially resulting in increased immune response to tumors (PMID: 25943534, PMID: 28214651). Imfinzi (durvalumab) is FDA approved for use in patients with urothelial carcinoma and unresectable, stage III non-small cell lung cancer, in combination with Imjudo (tremelimumab) and platinum-based chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC) without sensitizing EGFR or ALK mutations, in combination with etoposide and carboplatin or cisplatin in patients with extensive stage small cell lung cancer, in combination with cisplatin and gemcitabine in patients with locally advanced or metastatic biliary tract cancer, and in combination with Imjudo (tremelimumab) in adult patients with unresectable hepatocellular carcinoma (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Durvalumab Imfinzi MEDI4736 Immune Checkpoint Inhibitor 146 PD-L1/PD-1 antibody 114 Imfinzi (durvalumab) is a monoclonal antibody that binds to and inhibits PD-L1 (CD274), potentially resulting in increased immune response to tumors (PMID: 25943534, PMID: 28214651). Imfinzi (durvalumab) is FDA approved for use in patients with urothelial carcinoma and unresectable, stage III non-small cell lung cancer, in combination with Imjudo (tremelimumab) and platinum-based chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC) without sensitizing EGFR or ALK mutations, in combination with etoposide and carboplatin or cisplatin in patients with extensive stage small cell lung cancer, in combination with cisplatin and gemcitabine in patients with locally advanced or metastatic biliary tract cancer, and in combination with Imjudo (tremelimumab) in adult patients with unresectable hepatocellular carcinoma (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
CD274 positive transitional cell carcinoma predicted - sensitive Durvalumab Phase Ib/II Actionable In a Phase I/II trial, treatment with Imfinzi (durvalumab) resulted in an overall response rate (ORR) of 17.8% (34/191) in advanced urothelial carcinoma patients with an ORR of 27.6% (27/98) in patients with high PD-L1 (CD274) expression and 5.1% (4/79) in patients with low or negative PD-L1 (CD274), and similar complete response rates between the two groups (PMID: 28817753; NCT01693562). 28817753
MSH2 negative endometrial cancer sensitive Durvalumab Guideline Actionable Imfinzi (durvalumab) is included in guidelines for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) endometrial cancer who have failed platinum-based therapy (PMID: 35690222; ESMO.org). detail... 35690222
MSH2 negative endometrial cancer sensitive Durvalumab Phase II Actionable In a Phase II trial (PHAEDRA), Imfinzi (durvalumab) treatment resulted in superior objective tumor response rate (47%, 17/36, 6 complete responses, 11 partial responses (PR) vs 3%, 1/35, 1 PR) and median progression-free survival (8.3 vs 1.8 mo) in patients with mismatch repair deficient (dMMR, defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) advanced endometrial cancer compared to mismatch repair proficient patients (PMID: 34103352; NCT03015129). 34103352
MSH2 negative endometrial cancer sensitive Durvalumab Guideline Actionable Immune checkpoint inhibitor monotherapy including Imfinzi (durvalumab) is included in the Pan-Asian Guidelines Adaptation (PAGA) for patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) recurrent or metastatic endometrial cancer who have failed prior platinum-based chemotherapy (PMID: 36696825; ESMO.org). 36696825 detail...
MLH1 negative endometrial cancer sensitive Durvalumab Guideline Actionable Immune checkpoint inhibitor monotherapy including Imfinzi (durvalumab) is included in the Pan-Asian Guidelines Adaptation (PAGA) for patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) recurrent or metastatic endometrial cancer who have failed prior platinum-based chemotherapy (PMID: 36696825; ESMO.org). 36696825 detail...
MLH1 negative endometrial cancer sensitive Durvalumab Phase II Actionable In a Phase II trial (PHAEDRA), Imfinzi (durvalumab) treatment resulted in superior objective tumor response rate (47%, 17/36, 6 complete responses, 11 partial responses (PR) vs 3%, 1/35, 1 PR) and median progression-free survival (8.3 vs 1.8 mo) in patients with mismatch repair deficient (dMMR, defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) advanced endometrial cancer compared to mismatch repair proficient patients (PMID: 34103352; NCT03015129). 34103352
MLH1 negative endometrial cancer sensitive Durvalumab Guideline Actionable Imfinzi (durvalumab) is included in guidelines for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) endometrial cancer who have failed platinum-based therapy (PMID: 35690222; ESMO.org). 35690222 detail...
MSH6 negative endometrial cancer predicted - sensitive Durvalumab Guideline Actionable Imfinzi (durvalumab) is included in guidelines for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) endometrial cancer who have failed platinum-based therapy (PMID: 35690222; ESMO.org). detail... 35690222
MSH6 negative endometrial cancer predicted - sensitive Durvalumab Guideline Actionable Immune checkpoint inhibitor monotherapy including Imfinzi (durvalumab) is included in the Pan-Asian Guidelines Adaptation (PAGA) for patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) recurrent or metastatic endometrial cancer who have failed prior platinum-based chemotherapy (PMID: 36696825; ESMO.org). 36696825 detail...
MSH6 negative endometrial cancer predicted - sensitive Durvalumab Phase II Actionable In a Phase II trial (PHAEDRA), Imfinzi (durvalumab) treatment resulted in superior objective tumor response rate (47%, 17/36, 6 complete responses, 11 partial responses (PR) vs 3%, 1/35, 1 PR) and median progression-free survival (8.3 vs 1.8 mo) in patients with mismatch repair deficient (dMMR, defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) advanced endometrial cancer compared to mismatch repair proficient patients (PMID: 34103352; NCT03015129). 34103352
CD274 positive lung non-small cell carcinoma predicted - sensitive Durvalumab Phase II Actionable In a Phase II trial (ATLANTIC), Imfinzi (durvalumab) treatment resulted in superior objective response rate in non-small cell lung cancer patients with 25% or more tumor cells expressing CD274 (PD-L1) compared to patients with CD274 (PD-L1) expression in less than 25% of tumor cells, in both the cohort harboring EGFR and ALK mutations (12.2% vs 3.6%) and the EGFR and ALK wild-type cohort (16.4% vs 7.5%) (PMID: 29545095; NCT02087423). 29545095
ALK rearrange lung non-small cell carcinoma no benefit Durvalumab Guideline Actionable Immune checkpoint inhibitors including Opdivo (nivolumab), Keytruda (pembrolizumab), Tecentriq (atezolizumab), and Imfinzi (durvalumab) are not indicated for use as subsequent therapy in non-small cell lung cancer patients with ALK rearrangement (NCCN.org). detail...
ALK rearrange lung non-small cell carcinoma no benefit Durvalumab Clinical Study - Cohort Actionable In a retrospective analysis, PD-1/PD-L1 inhibitors (Opdivo (nivolumab), Keytruda (pembrolizumab), Imfinzi (durvalumab), or Tecentriq (atezolizumab)) resulted in lower objective response rate (3.6%, 1/28) in non-small cell lung cancer patients harboring EGFR mutations (22/28) or ALK rearrangement (6/28) compared to EGFR wild-type, ALK negative/unknown patients (23.3%, 7/30) (PMID: 27225694). 27225694
PMS2 negative endometrial cancer sensitive Durvalumab Phase II Actionable In a Phase II trial (PHAEDRA), Imfinzi (durvalumab) treatment resulted in superior objective tumor response rate (47%, 17/36, 6 complete responses, 11 partial responses (PR) vs 3%, 1/35, 1 PR) and median progression-free survival (8.3 vs 1.8 mo) in patients with mismatch repair deficient (dMMR, defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) advanced endometrial cancer compared to mismatch repair proficient patients (PMID: 34103352; NCT03015129). 34103352
PMS2 negative endometrial cancer sensitive Durvalumab Guideline Actionable Imfinzi (durvalumab) is included in guidelines for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) endometrial cancer who have failed platinum-based therapy (PMID: 35690222; ESMO.org). detail... 35690222
PMS2 negative endometrial cancer sensitive Durvalumab Guideline Actionable Immune checkpoint inhibitor monotherapy including Imfinzi (durvalumab) is included in the Pan-Asian Guidelines Adaptation (PAGA) for patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) recurrent or metastatic endometrial cancer who have failed prior platinum-based chemotherapy (PMID: 36696825; ESMO.org). 36696825 detail...

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT04716946 Phase II Durvalumab Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy Recruiting USA 0
NCT03144778 Phase I Durvalumab Durvalumab + Tremelimumab Checkpoint Inhibitors Assessment in Oropharynx Carcinoma (CIAO) Completed USA 0
NCT04351256 Phase II Durvalumab Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy (TRADE-hypo) Recruiting DEU 0
NCT03740893 Phase II Olaparib Ceralasertib Durvalumab PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Chemotherapy Resistant Residual Triple Negative Breast Cancer (PHOENIX) Recruiting GBR 0
NCT02087423 Phase II Durvalumab A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ATLANTIC) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT 9
NCT02549651 Phase I Durvalumab + Tremelimumab Durvalumab Danvatirsen + Durvalumab MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Diffuse Large B-cell Lymphoma (D4190C00023) Completed USA | GBR | FRA 1
NCT04430452 Phase II Durvalumab Durvalumab + Tremelimumab Hypofractionated Radiotherapy Followed by Durvalumab With or Without Tremelimumab for the Treatment of Liver Cancer After Progression on Prior PD-1 Inhibition Recruiting USA 0
NCT02669914 Phase II Durvalumab MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors Terminated USA 0
NCT04385368 Phase III Durvalumab Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC) (MERMAID-1) Completed USA | ITA | FRA | ESP | DEU | CAN | BEL | AUS 25
NCT03317158 Phase Ib/II Durvalumab BCG solution + Durvalumab ADAPT-BLADDER: Modern Immunotherpy in BCG-Relapsing Urothelial Carcinoma of the Bladder Recruiting USA 0
NCT03288532 Phase III Durvalumab Durvalumab + Tremelimumab Renal Adjuvant MultiPle Arm Randomised Trial (RAMPART) Recruiting GBR 0
NCT05718297 Phase II Brigatinib Durvalumab Brigatinib Post Definitive Chemo-radiotherapy in Patients With ALK-fusion Non-small Cell Lung Cancer (BOUNCE) Not yet recruiting ITA | GBR | FRA | ESP 1
NCT04322643 Phase II Durvalumab Pembrolizumab Avelumab Nivolumab Atezolizumab Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma Completed USA 0
NCT02793466 Phase I Durvalumab Durvalumab in Pediatric and Adolescent Patients Completed USA 0
NCT03975114 Phase II Durvalumab + Tremelimumab Durvalumab A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5) (MILES-5) Recruiting ITA 0
NCT03889275 Phase I Durvalumab Durvalumab + MEDI5395 MEDI5395 A Study of MEDI5395 in Combination With Durvalumab in Subjects With Select Advanced Solid Tumors Completed USA | GBR 0
NCT06223711 Phase II Durvalumab Cisplatin + Durvalumab + Etoposide Carboplatin + Durvalumab + Etoposide Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC Recruiting DEU 0
NCT03235869 Phase I Durvalumab Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma Withdrawn USA 0
NCT02733042 Phase Ib/II Rituximab Durvalumab + Lenalidomide + Rituximab Bendamustine + Durvalumab + Rituximab Durvalumab + Ibrutinib Durvalumab A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia (FUSION NHL 001) Completed USA | ITA | GBR | FRA | DEU 2
NCT03907475 Phase II Durvalumab Durvalumab + Nab-paclitaxel Capecitabine + Durvalumab Durvalumab + Pegylated liposomal doxorubicin Durvalumab + Gemcitabine Durvalumab + Paclitaxel Carboplatin + Durvalumab Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVA+ Study) Recruiting USA 0
NCT02227667 Phase II Durvalumab Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer Completed USA 0
NCT03150836 Phase II Durvalumab Durvalumab + Tremelimumab Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer Withdrawn USA 0
NCT03794544 Phase II Durvalumab + Oleclumab Danvatirsen + Durvalumab Durvalumab Durvalumab + Monalizumab Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer Completed USA | ITA | FRA | ESP | CAN 2
NCT02879617 Phase II Durvalumab A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients Completed USA 0
NCT03459846 Phase II Durvalumab + Olaparib Durvalumab A Phase II Study of Durvalumab and Olaparib Compared to Durvalumab in Patients With Advanced, Cisplatin Ineligible Bladder Cancer. (BAYOU) Active, not recruiting USA | ESP | CAN 4
NCT03833154 Phase III Durvalumab Durvalumab vs Placebo Following Stereotactic Body Radiation Therapy in Early Stage Non-small Cell Lung Cancer Patients (PACIFIC-4) Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 11
NCT02966587 Phase II Durvalumab Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Withdrawn USA 0
NCT03778957 Phase III Durvalumab Bevacizumab + Durvalumab A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma (EMERALD-1) Active, not recruiting USA | ITA | FRA | ESP | CAN | AUS 12
NCT02925234 Phase II Palbociclib Ribociclib Lenvatinib Ipilimumab + Nivolumab Trametinib Crizotinib Niraparib Selpercatinib Olaparib Erlotinib Erdafitinib Dabrafenib Dacomitinib Rucaparib Axitinib Panitumumab Pemigatinib Durvalumab Afatinib Entrectinib Tepotinib Alpelisib Atezolizumab + Bevacizumab Alectinib Regorafenib Cobimetinib + Vemurafenib Nilotinib Vismodegib Abemaciclib Sunitinib Nivolumab Cabozantinib Lorlatinib Talazoparib Dabrafenib + Trametinib Pembrolizumab Pertuzumab + Trastuzumab The Drug Rediscovery Protocol (DRUP Trial) (DRUP) Recruiting 1
NCT01993810 Phase III Carboplatin + Pemetrexed Disodium Durvalumab Cisplatin + Etoposide Carboplatin + Paclitaxel Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer Active, not recruiting USA 0
NCT04108481 Phase Ib/II Durvalumab Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer (iRE-C) Suspended USA 0
NCT02827838 Phase I Durvalumab Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer Completed USA 0
NCT03410615 Phase II Durvalumab + Tremelimumab Cisplatin Durvalumab Cisplatin Plus Radiotherapy vs Durvalumab Plus Radiotherapy Followed by Durvalumab vs Durvalumab Plus Radiotherapy Followed by Tremelimumab and Durvalumab in Intermediate Risk HPV-Positive Oropharyngeal SCC Active, not recruiting ITA | ESP | CAN | BEL 0
NCT02678182 Phase II Durvalumab Rucaparib Capecitabine Trastuzumab Capecitabine + Ramucirumab Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial (PLATFORM) Recruiting GBR 0
NCT05757843 Phase II Durvalumab Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab Recruiting USA 0
NCT03102047 Phase II Durvalumab Study of Durvalumab (MEDI4736) After Chemo-Radiation for Microsatellite Stable Stage II-IV Rectal Cancer Completed USA 0
NCT04092283 Phase III Carboplatin + Paclitaxel Cisplatin + Etoposide Cisplatin + Durvalumab + Etoposide Carboplatin + Durvalumab + Paclitaxel Durvalumab Cisplatin + Durvalumab + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Active, not recruiting USA 1
NCT04078152 FDA approved Durvalumab Durvalumab Long-Term Safety and Efficacy Study (WAVE) Active, not recruiting USA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 23
NCT03015129 Phase II Durvalumab Durvalumab + Tremelimumab A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer Completed USA 0
NCT03007407 Phase II Tremelimumab Durvalumab Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy Completed USA 0
NCT02891161 Phase Ib/II Durvalumab Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder Unknown status USA 0
NCT03215095 Phase I Durvalumab RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers Active, not recruiting USA 0
NCT05215106 Phase II Durvalumab Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva) (POP-DURVA) Recruiting FRA 0
NCT02503774 Phase I Durvalumab Oleclumab MEDI9447 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors Completed USA | AUS 1
NCT03258554 Phase II Cetuximab Durvalumab Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Stage III-IVB Head and Neck Cancer Who Cannot Take Cisplatin Active, not recruiting USA | CAN 0
NCT03818776 Phase I Durvalumab Proton Based Cardiac Sparing Accelerated Fractionated RadioTherapy in Unresectable NSCLC Terminated USA 0
NCT03084471 Phase III Durvalumab + Tremelimumab Durvalumab An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies. (STRONG) Completed USA | ITA | GBR | FRA | DEU | CAN 2
NCT03618134 Phase Ib/II Durvalumab Durvalumab + Tremelimumab Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner Terminated USA 0
NCT02551159 Phase III Cisplatin Durvalumab Carboplatin + Cetuximab + Fluorouracil Tremelimumab Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus Standard of Care (SOC) in SCCHN Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT 14
NCT04108026 Phase II Durvalumab Immunotherapy in Patient With Poor General Condition (SAVIMMUNE) Active, not recruiting FRA 0
NCT04602533 Phase II Cisplatin + Etoposide Durvalumab Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN) Recruiting DEU 0
NCT02886065 Phase I Durvalumab Durvalumab + PVX-410 Durvalumab + Lenalidomide + PVX-410 A Phase 1b Study of PVX-410, a Multi-Peptide Cancer Vaccine, and Durvalumab (Anti-PDL1) With and Without Lenalidomide for Patients With Smoldering Multiple Myeloma Active, not recruiting USA 0
NCT03277482 Phase I Durvalumab + Tremelimumab Durvalumab Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer Terminated USA 0
NCT03196401 Phase I Durvalumab A Study of Immunotherapy Plus Radiation Therapy to Stimulate Immunity in Solitary Bone Plasmacytoma Withdrawn USA 0
NCT03589547 Phase II Durvalumab Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung Active, not recruiting USA 0
NCT03003962 Phase III Durvalumab Cisplatin + Gemcitabine Carboplatin + Gemcitabine Carboplatin + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium Carboplatin + Paclitaxel Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL) Active, not recruiting USA | AUS 10
NCT06124118 Phase I Durvalumab Carboplatin + Paclitaxel Tumor Treating Fields for Locally Advanced NSCLC (NOVOCURE) Suspended USA 0
NCT03530397 Phase I Carboplatin + Pembrolizumab + Pemetrexed Disodium Durvalumab Carboplatin + MEDI5752 + Pemetrexed Disodium MEDI5752 A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors Recruiting USA | ITA | FRA | ESP | AUS 4
NCT04441138 Phase II Durvalumab Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III NSCLC (ESR1814205) Recruiting USA 0
NCT02319044 Phase II Durvalumab Tremelimumab Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck Completed USA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 7
NCT02453282 Phase III Durvalumab Cisplatin + Gemcitabine Carboplatin + Gemcitabine Carboplatin + Paclitaxel Tremelimumab Durvalumab + Tremelimumab Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC) (MYSTIC) Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL | AUS 9
NCT03784066 Phase Ib/II Durvalumab + Tremelimumab Durvalumab Durvalumab With or Without Tremelimumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cavity (DUTRELASCO) Active, not recruiting BEL 0
NCT03875573 Phase II Durvalumab Durvalumab + Oleclumab Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer: (Neo-CheckRay) Recruiting FRA | BEL 0
NCT05170204 Phase III Durvalumab Alectinib Pralsetinib Entrectinib A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC) Recruiting USA | GBR | ESP | CAN | BEL | AUS 17
NCT03056599 Phase I Pembrolizumab Avelumab Interferon gamma Olaratumab Trabectedin Nivolumab Gemcitabine Interferon alpha-2b Doxorubicin Atezolizumab Eribulin Ipilimumab Durvalumab Aldesleukin Bortezomib Docetaxel Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma Completed USA 0
NCT03237377 Phase II Durvalumab + Tremelimumab Durvalumab Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer Active, not recruiting USA | CAN 0
NCT04380636 Phase III Carboplatin Pemetrexed Disodium Pembrolizumab Cisplatin Durvalumab Etoposide Olaparib + Pembrolizumab Paclitaxel Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN 19
NCT04870112 Phase Ib/II Carboplatin + Cisplatin + Durvalumab + Etoposide Durvalumab A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung Cancer (SCope-D1) Completed USA | ESP 2
NCT02291055 Phase Ib/II Durvalumab ADXS11-001 Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combo In Cervical or HPV+ Head & Neck Cancer Terminated USA 0
NCT03618654 Phase I Durvalumab + Metformin Durvalumab Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma Active, not recruiting USA 0
NCT06083454 Phase I Durvalumab Durvalumab + Vitamin C Ascorbate With Durvalumab in Non-Small Cell Lung Cancer (NSCLC) Recruiting USA 0
NCT05211895 Phase III Durvalumab AB154 + Durvalumab A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC (PACIFIC-8) Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL 18
NCT03693300 Phase II Durvalumab A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Completed USA | ITA | GBR | FRA | ESP | DEU 0
NCT02221960 Phase I Durvalumab Efizonerimod A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors Completed USA | AUS 0
NCT03703297 Phase III Durvalumab Durvalumab + Tremelimumab Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Stage I-III Limited Disease Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC) Active, not recruiting USA | ITA | GBR | ESP | DEU | CAN | BEL 12
NCT02454933 Phase III Osimertinib Durvalumab Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours (CAURAL) Completed CAN 2
NCT02262741 Phase I Tremelimumab Durvalumab A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 With Tremelimumab or Tremelimumab Alone in Head and Neck Cancer Completed USA | CAN 0
NCT04395079 Phase II Tremelimumab Durvalumab Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies Active, not recruiting USA 0
NCT01693562 Phase Ib/II Durvalumab A Phase 1/2 Study to Evaluate MEDI4736 Completed USA | ITA | GBR | FRA | DEU | CAN | BEL 2
NCT04642469 Phase III Durvalumab Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy. (MERMAID-2) Active, not recruiting USA | ITA | FRA | ESP | CAN | BEL | AUS 18
NCT04073160 Phase I Durvalumab Durvalumab + Tremelimumab TRIO Bladder: A Phase Ib Study of Durvalumab (MEDI 4736) Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation, Based on Molecular Subtypes in Muscle-Invasive Bladder Cancer (TRIO Bladder) Withdrawn USA 0
NCT02639065 Phase II Durvalumab A Study of Durvalumab (MEDI4736) in Esophageal Cancer Completed USA 0
NCT02868632 Phase I Tremelimumab Durvalumab + Tremelimumab Durvalumab Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer Withdrawn USA 0
NCT02179671 Phase II Docetaxel + Selumetinib Gefitinib Durvalumab Osimertinib Tremelimumab Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer Completed USA 0
NCT02273375 Phase III Durvalumab Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC Active, not recruiting USA | ITA | FRA | ESP | CAN | AUS 13
NCT04334759 Phase III Durvalumab Cisplatin + Pemetrexed Disodium Cisplatin + Durvalumab + Pemetrexed Disodium DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma (DREAM3R) Active, not recruiting USA | AUS 1
NCT02904954 Phase II Durvalumab Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage IB and II Non-small Cell Lung Cancer Completed USA 0
NCT02499328 Phase Ib/II Danvatirsen + Durvalumab AZD5069 + Durvalumab Durvalumab Danvatirsen Study to Assess Combination of MEDI4736 With Either AZD9150 or AZD5069 in Patients With Metastatic Squamous Cell Carcinoma of Head and Neck Active, not recruiting USA | ITA | GBR | ESP | DEU | BEL 0
NCT04269200 Phase III Durvalumab Durvalumab + Olaparib Carboplatin + Durvalumab + Paclitaxel Carboplatin + Durvalumab + Olaparib + Paclitaxel Carboplatin + Paclitaxel Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer (DUO-E) Active, not recruiting USA | ESP | DEU | CAN | BEL | AUS 16
NCT03830866 Phase III Durvalumab Cisplatin + Durvalumab Carboplatin + Durvalumab Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA) (CALLA) Completed USA 14
NCT02527434 Phase II Durvalumab + Tremelimumab Durvalumab Study of Tremelimumab in Patients With Advanced Solid Tumors Completed USA | BEL 3
NCT04238637 Phase II Durvalumab Durvalumab + Tremelimumab Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC) Recruiting DEU 0
NCT02301130 Phase I Mogamulizumab Durvalumab Tremelimumab Study of Mogamulizumab + MEDI4736 and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors Completed USA 0
NCT02369874 Phase III Durvalumab + Tremelimumab Durvalumab Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer Completed USA | ITA | FRA | ESP | DEU | BEL | AUS 17
NCT04585490 Phase III Carboplatin + Durvalumab + Pemetrexed Disodium Durvalumab Carboplatin + Durvalumab + Paclitaxel Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC Recruiting USA 0
NCT04249362 Phase II Durvalumab Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy (DUART) Completed USA | ITA | FRA | ESP 2
NCT06045975 Phase II Durvalumab + Tremelimumab Durvalumab Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by Electroporation Ablation (DUMELEP) Not yet recruiting FRA 0
NCT05255653 Phase II Olaparib Medroxyprogesterone Carboplatin Megestrol acetate Paclitaxel Cisplatin Durvalumab Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (RAINBO) Recruiting GBR | FRA | CAN 1
NCT03635164 Phase I Durvalumab Radiotherapy With Durvalumab Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma Active, not recruiting USA 0
NCT03038477 Phase II Durvalumab A Study of Durvalumab in Patients With Borderline Resectable Pancreas Adenocarcinoma Following Neoadjuvant Therapy and Successful Surgical Resection Withdrawn USA 0
NCT03768570 Phase II Durvalumab Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer Active, not recruiting GBR | ESP | CAN 0
NCT04202809 Phase II Durvalumab Phase-II Trial of Induction Chemotherapy and Chemoradiotherapy Plus/Minus Durvalumab and Consolidation Immunotherapy in Patients With Resectable Stage III NSCLC. (ESPADURVA) Recruiting DEU 0
NCT04262869 Phase II Durvalumab + Pemetrexed Disodium Carboplatin + Durvalumab + Pemetrexed Disodium Carboplatin + Durvalumab + Paclitaxel Durvalumab Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung Cancer Withdrawn 0
NCT02546661 Phase I Danvatirsen + Durvalumab Durvalumab + Selumetinib AZD4547 Durvalumab + Olaparib Durvalumab AZD4547 + Durvalumab Durvalumab + Vistusertib Adavosertib + Durvalumab Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer (BISCAY) Active, not recruiting USA | GBR | FRA | ESP | CAN 0
NCT03741426 Phase II Durvalumab Cediranib Durvalumab + Olaparib Cediranib + Olaparib Olaparib WIRE - Novel Treatments in Renal Cell Cancer (WIRE) Recruiting GBR 0
NCT02899195 Phase II Cisplatin + Durvalumab + Pemetrexed Disodium Durvalumab Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma (PrE0505) Completed USA 0
NCT04866017 Phase III Durvalumab BGBA1217 + Tislelizumab Tislelizumab A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Patients With Stage III Unresectable Non-Small Cell Lung Cancer Terminated USA | AUS 2
NCT03026062 Phase II Tremelimumab Durvalumab + Tremelimumab Durvalumab Durvalumab and Tremelimumab in Combo Versus Sequential Recruiting USA 0
NCT05617963 Phase II Durvalumab Durvalumab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung Cancer Patients Whose Disease is Limited to the Thorax (DURVALUNG) Recruiting FRA 0
NCT05440864 Phase II Durvalumab + Tremelimumab Durvalumab Durvalumab and Tremelimumab in Resectable HCC ((NEOTOMA)) Recruiting ITA | ESP | CAN 0
NCT04892953 Phase II Carboplatin + Durvalumab + Paclitaxel Carboplatin + Durvalumab + Nab-paclitaxel Carboplatin + Durvalumab + Gemcitabine Durvalumab Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy Recruiting USA 0
NCT05221840 Phase III Durvalumab + Oleclumab Durvalumab Durvalumab + Monalizumab A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC-9) Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 14
NCT04003246 Phase III Durvalumab Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer Active, not recruiting USA 0
NCT03819465 Phase I Gemcitabine Durvalumab + Oleclumab Carboplatin Pemetrexed Disodium Nab-paclitaxel Danvatirsen + Durvalumab Cisplatin Durvalumab A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (MAGELLAN) Active, not recruiting USA | ESP | BEL | AUT 5
NCT02125461 Phase III Durvalumab A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC) Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 17
NCT03847649 Phase II Durvalumab Durvalumab + Prednisone Durvalumab Retreatment in Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Toxicity Recruiting CAN 0
NCT05696782 Phase II Durvalumab Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer Recruiting USA 0
NCT02340975 Phase Ib/II Durvalumab Tremelimumab A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma Completed USA | CAN 4
NCT03490760 Phase II Durvalumab Durvalumab and "Booster" Radiation in Metastatic Adenocarcinoma of the Pancreas Terminated USA 0
NCT04026412 Phase III Nivolumab Ipilimumab + Nivolumab Durvalumab A Study of Nivolumab and Ipilimumab in Untreated Patients With Stage 3 NSCLC That is Unable or Not Planned to be Removed by Surgery (CheckMate73L) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 18
NCT03610061 Phase I Durvalumab A Trial of Radiotherapy and Durvalumab in DLBCL and FL (RaDD) Active, not recruiting AUS 0
NCT05128630 Phase II Durvalumab Chemo-immunotherapy, Hypo-fractionated RT and Maintenance Immunotherapy for Stage III NSCLC. (DEDALUS) Recruiting ITA 0
NCT03916419 Phase II Durvalumab Carboplatin + Paclitaxel Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB and IIIA Non-small Cell Lung Cancer Active, not recruiting USA 0
NCT03206073 Phase Ib/II Durvalumab + Tremelimumab Durvalumab A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer Completed USA 0
NCT03148327 Phase Ib/II Durvalumab Astra Zeneca (Immuno Stereotactic Ablative Body Radiotherapy) ISABR Study: Randomized Phase I/II Study of Stereotactic Body Radiotherapy Active, not recruiting USA | AUS 0
NCT02207530 Phase II Durvalumab Phase II Study of MEDI4736 Monotherapy in the Treatment of Patients With Recurrent or Metastatic SCCHN. Completed USA | GBR | FRA | ESP | DEU | CAN | BEL 7
NCT02311361 Phase I Durvalumab Tremelimumab Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer Completed USA 0
NCT05568212 Phase II Durvalumab Durvalumab + Olaparib Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab Recruiting ITA 0
NCT03298451 Phase III Sorafenib Durvalumab + Tremelimumab Durvalumab Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN 11
NCT04387084 Phase I Durvalumab Pembrolizumab Avelumab Cemiplimab Atezolizumab Nivolumab Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy Recruiting USA 0
NCT04470674 Phase II Carboplatin + Durvalumab + Pemetrexed Disodium Durvalumab + Pemetrexed Disodium Durvalumab Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (>=50%) NSCLC Patients Withdrawn USA 0
NCT03847428 Phase III Durvalumab Bevacizumab + Durvalumab Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment (EMERALD-2) Active, not recruiting USA | ITA | FRA | DEU | CAN | AUT | AUS 17
NCT02866747 Phase Ib/II Durvalumab A Study Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and Durvalumab for Patients With Recurrent Glioblastoma (STERIMGLI) Active, not recruiting FRA 0
NCT02901548 Phase II Durvalumab Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder Terminated USA 0
NCT05713838 Phase II Durvalumab + Fluorouracil + Leucovorin + Oxaliplatin Docetaxel + Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin Durvalumab Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery Recruiting DEU 0
NCT02794883 Phase II Tremelimumab Durvalumab + Tremelimumab Durvalumab Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma Completed USA 0
NCT04364048 Phase II Pemetrexed Disodium Durvalumab Paclitaxel Etoposide Docetaxel Carboplatin Cisplatin Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer Active, not recruiting USA 0
NCT05303532 Phase III Durvalumab Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab (ROSY-D) Enrolling by invitation USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 19
NCT03283943 Phase I Durvalumab PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers. Unknown status CAN 0
NCT02616640 Phase I Pomalidomide Dexamethasone Durvalumab A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN 1
NCT03999710 Phase II Durvalumab Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer Active, not recruiting USA 0
NCT02154490 Phase II Docetaxel Nivolumab Palbociclib Durvalumab Ipilimumab + Nivolumab AZD4547 Taselisib Durvalumab + Tremelimumab Erlotinib + Rilotumumab Talazoparib Erlotinib Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Completed USA | CAN 0
NCT03601455 Phase II Durvalumab + Tremelimumab Durvalumab Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer Active, not recruiting USA 0
NCT03802747 Phase I Durvalumab + Tremelimumab Durvalumab Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases Withdrawn 0
NCT04062708 Phase II Cisplatin + Docetaxel + Durvalumab Durvalumab Cisplatin + Durvalumab + Pemetrexed Disodium CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer Active, not recruiting USA 0
NCT03801902 Phase I Durvalumab + Monalizumab Durvalumab Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), The ARCHON-1 Trial Recruiting USA 0
NCT02516241 Phase III Durvalumab + Tremelimumab Carboplatin + Cisplatin + Gemcitabine Durvalumab Study of MEDI4736 With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 14
NCT05043090 Phase III Durvalumab + Savolitinib Durvalumab Sunitinib Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC (SAMETA) Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 19
NCT04597671 Phase III Durvalumab Durvalumab and Low-dose PCI vs Durvalumab and Observation in Radically Treated Patients With Stage III NSCLC (NVALT28) (NVALT28) Recruiting 1
NCT04513925 Phase III Atezolizumab + Tiragolumab Durvalumab A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) (SKYSCRAPER-03) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 16
NCT03088059 Phase II Niraparib Durvalumab + Monalizumab Methotrexate Carboplatin Rogaratinib Mitomycin C Docetaxel Afatinib Paclitaxel Durvalumab Monalizumab Palbociclib Bleomycin Gemcitabine Fluorouracil Biomarker-based Study in R/M SCCHN (UPSTREAM) Active, not recruiting ITA | GBR | FRA | ESP | BEL 0
NCT03141359 Phase II Paclitaxel Cisplatin Durvalumab Carboplatin Etoposide Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC Active, not recruiting USA 0
NCT03822351 Phase II Durvalumab Durvalumab + Monalizumab Durvalumab + Oleclumab Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC (COAST) Completed USA | ITA | FRA | ESP | CAN 4
NCT03199040 Phase I Durvalumab Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy Terminated USA 0
NCT03011814 Phase Ib/II Durvalumab Durvalumab + Lenalidomide Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma Recruiting USA 0
NCT02537418 Phase I Cisplatin + Etoposide Durvalumab Tremelimumab Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Receiving Standard Chemotherapy Regimens Active, not recruiting CAN 0
NCT02352948 Phase III Durvalumab Vinorelbine Durvalumab + Tremelimumab Gemcitabine Erlotinib Tremelimumab A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ARCTIC) Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 17
NCT05443971 Phase II Durvalumab Durvalumab and Grid Therapy for the Treatment of Non-small Cell Lung Cancer in Patients Who Progressed During or After Treatment With the PACIFIC Regimen Recruiting USA 0
NCT04585477 Phase II Durvalumab Adjuvant Durvalumab for Early Stage NSCLC Patients With ctDNA Minimal Residual Disease Recruiting USA 0
NCT02205333 Phase Ib/II Rituximab MEDI6469 Tremelimumab Durvalumab A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies Terminated USA 0
NCT02788773 Phase II Durvalumab + Tremelimumab Durvalumab Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer Active, not recruiting CAN 0
NCT02592551 Phase II Durvalumab + Tremelimumab Durvalumab MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma Completed USA 0
NCT04786093 Phase II Durvalumab Durvalumab and Stereotactic Radiotherapy for Advanced NSCLC Recruiting USA 0
NCT03923270 Phase I Durvalumab + Tremelimumab Durvalumab Durvalumab + Olaparib Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer Active, not recruiting USA 0
NCT03095274 Phase II Durvalumab Tremelimumab Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin (DUNE) Completed ESP 0
NCT03775486 Phase II Durvalumab + Olaparib Cisplatin + Durvalumab + Pemetrexed Disodium Durvalumab Carboplatin + Durvalumab + Gemcitabine Carboplatin + Durvalumab + Pemetrexed Disodium Carboplatin + Durvalumab + Nab-paclitaxel Cisplatin + Durvalumab + Gemcitabine Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION) (ORION) Active, not recruiting USA | GBR | BEL 9
NCT02558894 Phase II Durvalumab Tremelimumab Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma Completed USA | ESP | DEU | CAN 2
NCT02519348 Phase II Tremelimumab Durvalumab A Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Unresectable Hepatocellular Carcinoma Active, not recruiting USA | ITA | ESP 6
NCT04216290 Phase II Cisplatin + Doxorubicin + Methotrexate + Vinblastine Durvalumab + Fluorouracil + Mitomycin C Gemcitabine Fluorouracil + Mitomycin C Durvalumab + Gemcitabine Cisplatin + Durvalumab Cisplatin + Gemcitabine Carboplatin + Gemcitabine Cisplatin Durvalumab A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, the INSPIRE Study Active, not recruiting USA 0
NCT02336165 Phase II Durvalumab Bevacizumab + Durvalumab Phase 2 Study of MEDI4736 in Patients With Glioblastoma Completed USA | AUS 0
NCT04543110 Phase II Durvalumab Radiation and Durvalumab Immunotherapy As Neoadjuvant Treatment for MIBC (RADIANT) Recruiting CAN 0
NCT03773666 Phase I Durvalumab + Oleclumab Durvalumab A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2) Completed USA 0
NCT04159974 Phase II Durvalumab Durvalumab + Tremelimumab RICE: Radio-Immuno-Chemotherapy of Cancer of the Esophagus (RICE) Recruiting DEU 0
NCT03837899 Phase Ib/II Durvalumab + Tremelimumab Durvalumab Durvalumab and Tremelimumab for Pediatric Malignancies Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU 1
NCT04944173 Phase II Durvalumab A Study of Durvalumab and Stereotactic Radiotherapy for Stage I Non-Small Cell Lung Cancer (SCION) Recruiting CAN 0
NCT03624231 Phase II Durvalumab Durvalumab + Tremelimumab Feasibility & Efficacy of Durvalumab+Tremelimumab+RT and Durvalumab+RT in Non-resect. Locally Advanced HPVnegativ HNSCC (DURTRE-RAD) Completed DEU 0
NCT02492867 Phase 0 Durvalumab Carboplatin + Paclitaxel A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer Completed USA 0
NCT05068232 Phase II Carboplatin + Durvalumab + Etoposide Durvalumab Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES) Recruiting USA 0
NCT02535078 Phase Ib/II Durvalumab Tebentafusp Tremelimumab Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Cutaneous Melanoma Completed USA 0
NCT04637594 Phase III Durvalumab Nivolumab Atezolizumab Avelumab Pembrolizumab Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy Active, not recruiting USA 0
NCT03245541 Phase Ib/II Durvalumab Study of Durvalumab and Stereotactive Ablative Body Radiotherapy in Advanced Pancreatic Adenocarcinoma (DurvaRad) Active, not recruiting USA 0
NCT04748419 Phase Ib/II Durvalumab Safety and Efficacy of Consolidative Hypofractionated Radiation Therapy (hfRT) for Boosting the Residual Primary Lung Cancer With Durvalumab Recruiting USA 0
NCT03164616 Phase III Durvalumab + Tremelimumab Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Cisplatin + Gemcitabine Carboplatin + Gemcitabine Durvalumab Carboplatin + Nab-paclitaxel Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). (POSEIDON) Active, not recruiting USA | GBR | DEU 16
NCT05925530 Phase II Durvalumab Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE) (MDT-BRIDGE) Not yet recruiting USA | ITA | FRA | ESP | DEU | CAN | AUT 4
NCT03840902 Phase II Carboplatin + Paclitaxel Bintrafusp alfa Cisplatin + Etoposide Durvalumab Bintrafusp alfa + Cisplatin + Etoposide Bintrafusp alfa + Carboplatin + Paclitaxel Bintrafusp alfa + Cisplatin + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) Terminated USA | FRA | ESP | DEU | CAN | BEL | AUS 8
NCT04001413 Phase II Durvalumab Durvalumab + MEDI0457 Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients Withdrawn USA 0


Additional content available in CKB BOOST